Checkpoint blockade therapy resistance in Hodgkin's lymphoma
نویسندگان
چکیده
منابع مشابه
Update on checkpoint blockade therapy for lymphoma
Although cancer cells express antigens recognizable to the immune system, tumors employ a number of diverse mechanisms aimed at subverting the host anti-tumor immune response. Tumor immune evasion pathways have been most thoroughly studied in solid tumors. However, emerging data has demonstrated that malignancies of hematopoietic origin are also able to co-opt their local environment in order t...
متن کاملImmune Checkpoint Blockade in Cancer Therapy.
Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) have demonstrated promise in a variety of malignancies. Ipilimumab (CTLA-4) and pembrolizumab (PD-1) are approved by the US Food and Drug Administration for the treatment of advanced melanoma, and additional regulatory appr...
متن کاملHodgkins Lymphoma in Cervical Lymphadenopathy
Objective: To determine the proportion of Hodgkins lymphoma in cervical lymphadenopathy. Methodology: This is a prospective study conducted at Isra University Hospital, Hyderabad between January 2002 to December 2006. The data was collected for all patients presenting with cervical lymphadenopathy during the above mentioned period. All the patients with cervical lymphadenopathy were subjected t...
متن کاملHodgkins lymphoma with HIV infection.
The association between Hodgkins Lymphoma (HL) with HIV is common in adults but rare in children. A 5 year old boy, known case of HIV on antiretroviral therapy, presented with prolonged fever, multiple enlarged lymph nodes along with hepatosplenomegaly. A diagnosis of Hodgkins lymphoma was entertained on histopathological examination; further subtyping was done by immunohistochemistry.
متن کاملHodgkins lymphoma: treatment and prognosis
Supported in part by a grant provided by IASIS a non-profit organization raising funds for Research in Leukemias, Lymphomas and related disorders come. AAS I/IIA are definitely non-advanced for most study groups. Non-advanced stages are further classified as early or early favourable and intermediate or early unfavourable according to the presence of adverse features. Table 1 summariz...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Lancet
سال: 2018
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(18)31867-1